Solving the insoluble

The majority of small-molecule therapeutics that emerge from today’s discovery pipelines are too poorly water-soluble to allow for reproducible absorption after oral intake. This solubility problem dramatically complicates pharmaceutical development and prevents patients from accessing potentially life-saving therapeutics.

At SeraNovo, we design, develop and GMP-manufacture solubility-enhancing formulations using our proprietary technology platform that harnesses the unique benefits of deep eutectic solvents.

We are a growing company and always have positions open for scientists, please see for mor details.

Last updated: March 2022

Niall Hodgins (co-founder)
Ian Degeling (co-founder)
Startup activities

Winner Venture Challenge Fall 2018

SeraNovo Winner Venture Challenge Fall 2018

Niall Hodgins